Not yet recruiting
A study to compare heart failure medicines in one combined pill with usual care.
2026-526510-90-00· Phase 3· Institut De Recherches Internationales Servier IRIS· Source
Recruiting
Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation
NCT07792239· Phase 2· Xyra, LLC· Source
Recruiting
A Phase 2 Study of Lesigercept (YH35324) in Adult Patients with Chronic Spontaneous Urticaria (CLEAR)
2025-524006-14-00· Phase 2· Yuhan Corp.· Source
Recruiting
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria
2025-522878-36-00· Phase 3· Celldex Therapeutics Inc.· Source
Recruiting
Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
NCT07415551· Phase 2· Yuhan Corporation· Source
Contact: JinHyun Choi
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes
2025-521670-34-00· Phase 3· Novartis Pharma AG· Source
Recruiting
Poland-Italy Aortic Research Bridge Real World Registry
NCT07476196· American Heart of Poland· Source
Contact: Grzegorz Oszkinis, Prof
Recruiting
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
NCT07201129· Phase 3· Viatris Innovation GmbH· Source
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285· Phase 3· Novo Nordisk A/S· Source
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531· Phase 2· SAb Biotherapeutics, Inc.· Source
Recruiting
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
NCT07195149· Phase 3· Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· Phase 3· Amgen Inc.· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
NCT06929806· Phase 3· Pharmacosmos A/S· Source
Recruiting
BOOSTER – Multicenter, Open Label, Randomized Control Phase III Trial Comparing the Efficacy and Safety of Two Rituximab Regimens in Maintenance Therapy for Relapsing Nephrotic Syndrome Due to Podocytopathies in Adults.
(B cell Depletion Therapy to Improve Outcomes of Relapsing STERoid-sensitive Podocytopathies in Adults – BOOSTER trial)
2023-509755-13-00· Phase 3· Medical University Of Lodz· Source
Recruiting
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
NCT06688331· Phase 2· PolTREG S.A.· Source
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574· Phase 3· Cytokinetics· Source
Recruiting
EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn
NCT06675617· Intressa Vascular SA· Source
Contact: Virginie Martin
Active, not recruiting
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202· Phase 3· Celldex Therapeutics· Source
Active, not recruiting
A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C
NCT05975021· Phase 1/2· Windtree Therapeutics· Source
Recruiting
Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes
NCT05957055· Phase 2· Medical University of Lodz· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610· Phase 3· Hoffmann-La Roche· Source
Recruiting
Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion
NCT05759078· Phase 4· Wroclaw Medical University· Source
Contact: Marta Duda-Sikuła
Active, not recruiting
Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)
NCT05279651· Phase 3· Jagiellonian University· Source
Active, not recruiting
Empagliflozin and dapagliflozin for improvement of outcome in patients with acute heart failure
2024-518685-27-00· Phase 3· Medical University Of Warsaw· Source
Active, not recruiting
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133· Phase 3· AstraZeneca· Source